Literature DB >> 1859075

T lymphocyte activation in patients with active tuberculosis.

C H Chan1, K N Lai, J C Leung, C K Lai.   

Abstract

Soluble interleukin-2 receptor (sIL-2R) is a marker of T lymphocyte activation. We measured the amount of serum sIL-2R in 35 patients with active tuberculosis before the initiation of antituberculous treatment. Twenty had pulmonary parenchymal lesion, 8 had tuberculous pleural effusion, and 7 had tuberculous lymphadenitis. The serum sIL-2R values were markedly elevated in patients with pulmonary tuberculosis (parenchymal lesion and pleural effusion) compared with patients with tuberculous lymphadenitis (2,612 +/- 536 versus 538 +/- 121 U/ml, p = 0.023), old, inactive tuberculosis (335 +/- 23 U/ml, p = 0.001), and normal control subjects (376 +/- 38 U/ml, p = 0.001). No significant difference was found between patients with parenchymal lesion and those with tuberculous pleural effusion. There was a positive correlation between serum sIL-2R values and the extent of disease on chest radiograph (r = 0.58, p less than 0.001). We conclude that the amount of sIL-2R may be a useful marker of disease activity and extent of involvement in patients with active tuberculous lesions.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1859075     DOI: 10.1164/ajrccm/144.2.458

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  3 in total

1.  Circulating adhesion molecules in tuberculosis.

Authors:  C K Lai; K C Wong; C H Chan; S S Ho; S Y Chung; D O Haskard; K N Lai
Journal:  Clin Exp Immunol       Date:  1993-12       Impact factor: 4.330

2.  Impact of tuberculosis in children with idiopathic nephrotic syndrome.

Authors:  U Kala; L S Milner; D Jacobs; P D Thomson
Journal:  Pediatr Nephrol       Date:  1993-08       Impact factor: 3.714

3.  Role of soluble interleukin-2 receptor levels in patients with latent tuberculosis.

Authors:  David Shitrit; Gabriel Izbicki; Ariella Bar-Gil Shitrit; Meir Raz; Jaquline Sulkes; Mordechai Rehven Kramer
Journal:  Lung       Date:  2006 Jan-Feb       Impact factor: 3.777

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.